Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG

March 24th 2025

A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.

Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in Advanced Liposarcoma

March 24th 2025

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

EMA to Review Application for Expanded Indication for Sugemalimab in Unresectable NSCLC

March 24th 2025

A Type II variation application has been submitted to the EMA for the expanded approval of sugemalimab for unresectable stage III NSCLC.

NMPA Approves sNDA for Toripalimab Plus Bevacizumab in Advanced HCC

March 24th 2025

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

Emerging Therapies in Myelofibrosis Could Extend Beyond JAK Inhibitors

March 24th 2025

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

Dr Gupta on Avelumab Maintenance Therapy in Advanced Urothelial Cancer With Diabetes

March 21st 2025

Shilpa Gupta, MD, discusses OS outcomes with first-line maintenance avelumab plus BSC in advanced urothelial carcinoma based on diabetes mellitus.

Dr Cho on Niraparib Rechallenge Plus Bevacizumab in Platinum-Sensitive, Recurrent Ovarian Cancer

March 21st 2025

Hyun-Woong Cho, MD, PhD, discusses the efficacy of maintenance therapy with niraparib plus bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Oncologists Call for Equity and Female Representation in Research During Women’s History Month

March 21st 2025

Shruti Patel, MD, highlights women making strides to improve cancer care and the need for equitable gender representation among oncology researchers.

Bioengineered Bone Marrow Model Reveals Potential New Strategies for Osteosarcoma Metastasis Control

March 21st 2025

R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant R/R Follicular Lymphoma

March 21st 2025

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

PLN-101095/Pembrolizumab Has Early Activity in ICI-Refractory Advanced Solid Tumors

March 21st 2025

PLN-101095 plus pembrolizumab was safe and active in immune checkpoint inhibitor–refractory advanced solid tumors.

Emerging ADCs, Biomarker-Driven Treatments, and Diagnostic Advancements Take Center Stage at the SGO Annual Meeting

March 21st 2025

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends in gynecologic cancer care discussed during the 2025 SGO Annual Meeting.

Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

March 20th 2025

Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.

Dr Bhat on the Influence of MPN Risk Stratification on Treatment Decision-Making

March 20th 2025

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

Comprehensive Communication Regarding CRC Surgery and Postoperative Complications Is Crucial

March 20th 2025

Andreas M. Kaiser, MD, discusses strategies to reduce postoperative complications and determine surgical eligibility in patients with CRC.

How Medical Physicists Contribute to Optimized Oncologic Outcomes: With D. Ross Camidge, MD, PhD; Alexandra Rink, PhD

March 19th 2025

Drs Camidge and Rink discuss Dr Rink's career in medical physics and the importance of multidisciplinary collaboration to deliver optimal patient care.

Avapritinib Leads a Charge of Novel Targeted Therapies for Indolent Systemic Mastocytosis

March 19th 2025

Tsewang Tashi, MD, discusses the efficacy and tolerability of targeted therapies like avapritinib for patients with indolent systemic mastocytosis.

FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma

March 19th 2025

The FDA approved pembrolizumab, trastuzumab, and chemotherapy for HER2-positive, PD-L1–positive gastric/GEJ adenocarcinoma.

HLX22 Receives FDA Orphan Drug Designation in Gastric Cancer

March 19th 2025

The FDA has granted orphan drug designation to HLX22 for the treatment of patients with gastric cancer based on positive data from the HLX22-GC-201 study.

Fruquintinib/Sintilimab Generates Favorable PFS Outcomes in Advanced RCC

March 19th 2025

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.